Q-omics provides the consensus-scored MET profile across patient tissues and cancer cell-line models. MET expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MET is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, MET RNA expression shows 18,805 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where MET shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MET — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MET survival associations across molecular data types. MET RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MET RNA expression–survival associations across cancer types. High MET expression shows unfavorable associations in UVM, PAAD, LGG, STAD, MESO and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MET RNA expression.
This table summarizes MET tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MET. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MET shows higher tumor expression in HNSC, COAD, KIRP, THCA, KIRC and STAD. The HNSC box plot shows higher MET RNA expression in tumor versus normal tissue (log2 FC = +2.324, t-test p < 0.001).
This table shows molecular features associated with MET in patient tissues and cancer cell lines. In patient samples, MET shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MET RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
